Clovis Oncology Inc (NASDAQ:CLVS) insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $54.09, for a total value of $162,270.00. Following the completion of the sale, the insider now directly owns 180,571 shares in the company, valued at $9,767,085.39. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Clovis Oncology Inc (NASDAQ:CLVS) traded down $0.43 during mid-day trading on Friday, reaching $54.15. The company had a trading volume of 675,404 shares, compared to its average volume of 1,350,000. The company has a market cap of $2,650.00, a PE ratio of -6.54 and a beta of 1.05. Clovis Oncology Inc has a fifty-two week low of $45.42 and a fifty-two week high of $99.45. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.19 and a quick ratio of 3.16.
A number of analysts have recently commented on the company. BidaskClub cut Clovis Oncology from a “sell” rating to a “strong sell” rating in a research report on Friday, February 9th. Leerink Swann reissued an “outperform” rating and issued a $90.00 price target (down from $107.00) on shares of Clovis Oncology in a research report on Wednesday, November 15th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Clovis Oncology in a research report on Thursday, January 11th. Credit Suisse Group set a $86.00 price target on Clovis Oncology and gave the stock a “buy” rating in a research report on Thursday, January 18th. They noted that the move was a valuation call. Finally, Barclays initiated coverage on Clovis Oncology in a research report on Monday, October 23rd. They issued an “overweight” rating and a $105.00 price target on the stock. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the company’s stock. Clovis Oncology presently has a consensus rating of “Hold” and an average target price of $90.43.
Hedge funds have recently added to or reduced their stakes in the stock. Capital Analysts LLC purchased a new stake in Clovis Oncology during the 3rd quarter valued at $111,000. Phocas Financial Corp. purchased a new stake in Clovis Oncology during the 2nd quarter valued at $112,000. Cypress Capital Management LLC WY raised its stake in Clovis Oncology by 272.7% during the 3rd quarter. Cypress Capital Management LLC WY now owns 2,050 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 1,500 shares during the last quarter. Commonwealth Equity Services Inc purchased a new stake in Clovis Oncology during the 3rd quarter valued at $239,000. Finally, First Republic Investment Management Inc. purchased a new stake in Clovis Oncology during the 3rd quarter valued at $251,000.
ILLEGAL ACTIVITY WARNING: “Clovis Oncology Inc (CLVS) Insider Gillian C. Ivers-Read Sells 3,000 Shares” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/16/clovis-oncology-inc-clvs-insider-gillian-c-ivers-read-sells-3000-shares.html.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.